Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
Radiat Res. 2013 Jul;180(1):34-43. doi: 10.1667/RR3255.1. Epub 2013 Jun 7.
Radiation dermatitis occurs in approximately 95% of patients receiving radiotherapy (RT) for breast cancer. We conducted a randomized, double-blind, placebo-controlled clinical trial to assess the ability of curcumin to reduce radiation dermatitis severity in 30 breast cancer patients. Eligible patients were adult females with noninflammatory breast cancer or carcinoma in situ prescribed RT without concurrent chemotherapy. Randomized patients took 2.0 grams of curcumin or placebo orally three times per day (i.e., 6.0 grams daily) throughout their course of RT. Weekly assessments included Radiation Dermatitis Severity (RDS) score, presence of moist desquamation, redness measurement, McGill Pain Questionnaire-Short Form and Symptom Inventory questionnaire. The 30 evaluable patients were primarily white (90%) and had a mean age of 58.1 years. Standard pooled variances t test showed that curcumin reduced RDS at end of treatment compared to placebo (mean RDS = 2.6 vs. 3.4; P = 0.008). Fisher's exact test revealed that fewer curcumin-treated patients had moist desquamation (28.6% vs. 87.5%; P = 0.002). No significant differences were observed between arms for demographics, compliance, radiation skin dose, redness, pain or symptoms. In conclusion, oral curcumin, 6.0 g daily during radiotherapy, reduced the severity of radiation dermatitis in breast cancer patients.
放射性皮炎发生于约 95%接受乳腺癌放射治疗（RT）的患者。我们开展了一项随机、双盲、安慰剂对照临床试验，旨在评估姜黄素减轻 30 例乳腺癌患者放射性皮炎严重程度的能力。符合条件的患者为接受 RT 而未同时接受化疗的非炎性乳腺癌或原位癌成年女性。随机分组患者在 RT 全程中每日口服 2.0 克姜黄素或安慰剂，每日 3 次（即 6.0 克）。每周评估包括放射性皮炎严重程度（RDS）评分、湿性脱皮的存在、红斑测量、麦吉尔疼痛问卷-短表和症状清单问卷。30 例可评估患者主要为白人（90%），平均年龄为 58.1 岁。标准合并方差 t 检验显示，与安慰剂相比，姜黄素在治疗结束时降低了 RDS（平均 RDS=2.6 比 3.4；P=0.008）。Fisher 确切检验显示，接受姜黄素治疗的患者中湿性脱皮的发生率更低（28.6%比 87.5%；P=0.002）。两组间在人口统计学特征、依从性、放射皮肤剂量、红斑、疼痛或症状方面无显著差异。总之，在乳腺癌患者中，RT 期间每日口服 6.0 克姜黄素可减轻放射性皮炎的严重程度。
